Related Experiment Video
Updated: Feb 23, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.9K
Summary
Metastasis-free survival is a reliable predictor of overall survival in localized prostate cancer. This finding can speed up the assessment of new adjuvant therapies for patients.
Area of Science:
- Oncology
- Clinical Trials
Background:
- Localized prostate cancer management often involves adjuvant therapies.
- Evaluating treatment efficacy relies on survival outcomes.
Purpose of the Study:
- To determine if metastasis-free survival (MFS) is a valid surrogate for overall survival (OS) in localized prostate cancer.
- To assess the potential of MFS to accelerate clinical trial evaluations.
Main Methods:
- A meta-analysis of relevant clinical studies was conducted.
- Statistical methods were employed to evaluate the correlation between MFS and OS.
Main Results:
- Metastasis-free survival demonstrates a strong correlation with overall survival in localized prostate cancer.
- MFS emerged as a robust surrogate endpoint.
Conclusions:
- Metastasis-free survival is a validated surrogate for overall survival in localized prostate cancer.
- Utilizing MFS can expedite the evaluation of novel adjuvant therapies, benefiting patients.
